By addressing multiple pathways involved in AD pathology, such as amyloid and tau aggregation, lysosomal function and EV-mediated protein spread, combination therapies could provide a comprehensive approach to mitigating disease progression and improving patient outcomes. The gene discussed is MAPT; the disease is Alzheimer disease.